Today in our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort – Daniel Splatt and Michelle Tan highlight the benefits of a patent box system, much advocated but missing from our innovation ecosystem. The World Intellectual Property Organisation’s Global Innovation Index has revealed a steady decline in Australia’s knowledge, technology, and creative…
Australia’s R&D effort is focused around medical technologies and here in our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort – Dig Howitt of Cochlear outlines the way ahead to support innovation in the sector. Cochlear has long been a pioneer in innovation. It has reshaped hearing technology and made substantial contributions…
Faltering business expenditure on R&D is a major factor in Australia’s poor innovation performance. Today in our editorial series – Towards 3% R&D – Turbocharging Australia’s Innovation Effort – Dr John Howard identifies businesses’ failings. This is an edited excerpt (full paper link below). From 1981 to 1995, Australian businesses made steady progress in lifting…
Biotechnology giant CSL has reported net profit after tax for the six months ended December 31 of $1.9 billion, up 20 percent on the previous corresponding period. Underlying net profit was $2.02, set on revenue up 11 percent to $8.05 billion. CSL CEO and Managing Director Dr Paul McKenzie said: “Our strong first half result…
Biotechnology manufacturer CSL has failed to prove the efficacy of one of its most promising drugs under development – CSL112 (apolipoprotein A-I [human]). As recently as last year the Melbourne company was testing the drug in reducing the risk of follow on adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI) or…
Melbourne biotechnology giant CSL has hit back at doubters posting a massive rise in revenues for the year. The company, which has been questioned by analysts about its recent acquisition of the Vifor pharmaceutical business, reported revenues up 31 percent at constant currency value to $13.31 billion for FY23. Sales for CSL Vifor in the…
What were the five biggest stories of the week? Here’s what visitors to this site were reading. 5) AUKUS technology sharing comes a step closer Australian access to foreign technologies on a range of cutting edge industrial technologies is a step closer following progress in the US Senate to the provision of exemptions from export…
Australia’s largest manufacturer, biotechnology and vaccine producer CSL’s brand value has jumped more than 30 percent over the past year to make it the fastest growing brand in its industry, according to a new report from consultant Brand Finance. The report lists CSL’s brand value at US$1.3 billion, which is up 80 percent since 2020.…
STÄRKE expands into injection moulding STÄRKE Advanced Manufacturing Group has announced the acquisition of the complete assets of RIAN INDUSTRIES, a 22 machine injection moulding business in Melbourne. Group CEO Al Jawhari said the company would be known as STÄRKE INJECTION MOULDING PTY. LTD. and combined with the company’s facilities in Adelaide and Detroit, Michigan…
A new Australian Research Council (ARC) Hub to help forge an internationally competitive Australian biopharmaceutical sector using digitisation and artificial intelligence (AI) in pharmaceutical manufacturing has been launched at the University of Melbourne. ARC Acting CEO Dr Richard Johnson inaugrated the ARC Digital Bioprocess Development Hub – a five-year, $18 million research programme, which has…
